Strategic partnerships Position TechnoVax as a partner for vaccine development and manufacturing with Innovative Biotech and similar private biotech players that already collaborate on VLP platforms, leveraging non-dilutive funding history to attract co-development or milestone-based deals.

VLP leadership Highlight the advanced Virus-Like Particle platform as a differentiator for univeral flu, inhaled powder vaccine, and RSV programs, targeting biopharma manufacturers and contract development and manufacturing organizations seeking scalable vaccine technologies.

Non-dilutive traction Emphasize $5M+ in non-dilutive funding to de-risk partnerships and attract investors, grants, and government programs; offer collaboration terms that align with public funding cycles to accelerate joint development timelines.

Global access appeal Market the inhaled powder vaccine concept as a route to cold-chain-free, self-administered delivery, aligning with global health organizations and emerging markets focusing on distribution efficiency and rapid deployment in low-resource settings.

Pipeline co-creation Leverage the three lead candidates to propose multi-program licensing, co-development, or manufacturing agreements with larger biotech and CMOs seeking diversified vaccine portfolios and entry into next-generation vaccine technologies.